Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 4, 1999, Pages 917-928

  Karlan, Beth Y ^a   Baldwin, Rae Lynn ^b   Lopez Luevanos, Eloise ^b   Raffel, Leslie J ^b   Barbuto, Denise ^b   Narod, Steven ^b   Platt, Lawrence D ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

Hereditary ovarian cancer; Multifocal; Ovarian cancer screening; Peritoneal serous papillary carcinoma

Indexed keywords

CA 125 ANTIGEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PAPILLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032903692     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70663-0     Document Type: Conference Paper

References (36)

1. 1. National Institutes of Health Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA 1995;273:-191-7.
2. 2. Szabo CI, King MC. Inherited breast and ovarian cancer. Hum Mol Genet 1995;4:1811-7.
3. 3. Karlan BY, Raffel LJ, Crvenkovic G, Snirt C, Chen MD, Lopez E, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early rcsults. Am J Obstet Gynecol 1993;169:494-501.
4. 4. Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol 1994;55:S28-S33.
5. 5. Karlan BY. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J Cell Biochem 1995;23:227-32.
6. 6. Karlan BY, Platt LD. Ovarian cancer screening: the role of ultrasound in early detection. Cancer 1995;76:2011-5.
7. 7. Cane P, Azen C, Lopez F, Platt LD, Karlan BY. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol 1995;57:240-5.
8. 8. Bloss JD, Liao S-Y, Buller RE, Manetta A, Berman ML, McMeekin S, et al. Extraovarian peritoneal serons papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51.
9. 9. Karlan BY, Jones J, Slamon DJ, Lagasse LD. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 1994;53:70-7.
10. 10. Tonin P, Weber B, Offit K, Couch F, Rebbeck RH, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Med 1996;2:1179-83.
11. 11. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 1996;14:185-7.
12. 12. Di-Xia C, Schwartz PE, Xinguo L, Zhau Y. Evalualion of CA125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72:23-7.
13. 13. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65:408-14.
14. 14. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 1993;306:1030-4.
15. 15. Bourne TH, Campbell S, Reynolds RM, Whitehead MI, Hampson J, Roystson P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonograpby and colour blood flow imaging. BMJ 1993;306:1025-9.
16. 16. Bourne TH, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford JB, et al. The potential role of serum CA125 in an ultrasonnd-based screening program for familial ovarian cancer. Gynecol Oncol 1994;52:379-85.
17. 17. Heintz APM, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol 1985;66:127-35.
18. 18. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Karlan B, et al. UNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
19. 19. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1998;.53:2128-32.
20. 20. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
21. 21. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
22. 22. Cirisano FD, Karlan BY. The rule of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Invest 1996;3:99-105.
23. 23. Scambia G, Ferrandina G, Marone M, Panici PB, Giannitelli C, Piantelli M, et al. nm23 in ovarian cancer: Correlalion with clinical outcome and other clinicopalhologic and biochemical prognostic parameters. J Clin Oncol 1996;14:334-42.
24. 24. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-8.
25. 25. Li S, Han H, Resnik E, Carcangio ML, Schwartz PE, Yang-Feng TL. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993;51:21-5.
26. 26. Gallion HH, Guarino A, DePriest PD, van Nagell JR, Vaccarello L, Berek JS, et al. Evidence for a unifocal origin in familial ovarian cancer Am J Obstet Gynecol 1996;174:1102-8.
27. 27. Fromm CL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95.
28. 28. Muto MG, Welch WK, Mok C-H, Bandera CA, Fishbaught PM, Tsao SW, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995;55:490-2.
29. 29. Schorge JO, Muto MG, Welch WR, Berkowitz RS, Mok SC. Androgen receptor genetic analysis of the X-chromosome inactivation pattern in patients with papillary serous carcinoma of the peritoneum. Gynecol Oncol 1998;68:89.
30. 30. Moll TM, Valea F, Chumas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol 1997;16:156-62.
31. 31. Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 1997;79:1587-94.
32. 32. Bandera C, Muto M, Berkowitz R, Rubin S, Boyd J, Mok S. Germline BRCA1 mutations in women with papillary serous carcinoma of the peritoneum (PSCP). In: Proceedings of the American Association for Cancer Research; 1997; San Diego, California, Philadelphia: The Association; 1997.
33. 33. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795-7.
34. 34. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751-5.
35. 35. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst 1995;17:33-5.
36. 36. Skates SJ, Xu F-J, Yu Y-H, Sjovall K, Einhorn N, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004-10.